effect
antivir
develop
specif
virus
hiv
hepat
c
viru
influenza
viru
one
bugon
drug
approach
antivir
drug
develop
success
may
inadequ
respond
increas
divers
virus
caus
signific
diseas
human
major
viral
pathogen
caus
emerg
reemerg
infecti
diseas
membraneenvelop
virus
requir
fusion
viral
cell
membran
viru
entri
therefor
antivir
target
membran
fusion
process
repres
new
paradigm
broadspectrum
antivir
discoveri
review
discuss
mechan
respons
fusion
viru
cell
membran
explor
broadspectrum
antivir
target
process
prevent
viru
entri
emerg
infecti
diseas
pose
constant
threat
global
health
global
economi
vast
major
diseas
zoonos
occur
human
environment
factor
forc
unintend
overlap
previous
distinct
ecolog
nich
overlap
increas
chanc
virus
jump
host
speci
andor
gener
new
crossov
speci
case
zoonot
virus
ill
adapt
new
human
host
highli
pathogen
infect
virus
lead
rapidli
progress
sever
diseas
high
fatal
rate
filovirus
ebola
viru
ebov
marburg
viru
henipavirus
hendra
viru
nipah
viru
niv
coronavirus
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
lethal
exampl
recent
zoonos
addit
virus
famili
arenavirida
junin
viru
lassa
viru
bunyavirida
includ
divers
hantavirus
rift
valley
fever
viru
rvfv
flavivirida
dengu
viru
denv
west
nile
viru
wnv
may
repres
even
greater
threat
futur
global
climat
chang
increas
geograph
rang
anim
arthropod
host
hiv
arguabl
obviou
exampl
zoonosi
disrupt
global
health
economi
public
health
intervent
combin
concert
effort
develop
specif
drug
hiv
yield
laudabl
success
develop
specif
drug
target
differ
aspect
hiv
life
cycl
result
potent
antiretrovir
combin
drug
therapi
save
innumer
live
success
antiretrovir
drug
develop
recapitul
latest
gener
potent
diseaseerad
antihepat
c
viru
hcv
drug
target
specif
hcv
protein
success
showcas
power
tradit
pathogenspecif
drug
develop
paradigm
well
practis
pharmaceut
industri
despit
mani
success
one
bugon
drug
approach
antivir
drug
develop
strategi
may
inadequ
respond
increas
divers
virus
caus
signific
diseas
human
exampl
industri
antivir
drug
develop
understand
driven
econom
incent
mean
list
clinic
activ
antivir
approv
us
fda
european
medicin
agenc
ema
domin
antihiv
antihcv
antiherpesviru
antiinfluenza
viru
drug
given
increas
number
emerg
reemerg
viral
zoonos
close
half
million
unknown
mammalian
virus
predict
present
wildlif
reservoir
remain
discov
tradit
virusspecif
paradigm
antivir
drug
develop
unlik
result
time
effect
therapi
numer
pathogen
caus
rare
lethal
infect
observ
underscor
need
broadspectrum
antivir
act
multipl
virus
target
common
life
cycl
rather
specif
viral
protein
importantli
ribavirin
current
broadspectrum
antivir
purportedli
effect
variou
rna
virus
consensu
mechan
action
moa
perhap
ribavirin
multipl
mode
action
work
differ
way
differ
virus
ideal
broadspectrum
antivir
one
target
common
essenti
viral
function
properti
notabl
vast
major
viral
pathogen
present
emerg
infecti
diseasespathogen
list
us
nation
institut
allergi
infecti
diseas
niaid
smallpox
viru
viral
haemorrhag
fever
virus
arenavirus
bunyavirus
flavivirus
filovirus
henipavirus
coronavirus
arbovirus
caus
encephalitid
wnv
cite
membraneenvelop
virus
order
virus
replic
need
gain
access
metabol
resourc
within
host
cell
occur
process
involv
viru
host
cell
membran
fusion
requir
viral
fusion
protein
take
place
either
directli
cell
surfac
later
endocyt
compart
despit
divers
array
viral
fusion
protein
vari
moa
underli
biophys
biochem
featur
membran
fusion
process
common
among
envelop
virus
target
conserv
featur
biophys
properti
viral
lipid
membran
host
factor
requir
effici
membran
fusion
emerg
new
paradigm
develop
broadspectrum
antivir
furthermor
featur
encod
viral
genom
suggest
antivir
strategi
also
probabl
increas
barrier
resist
review
discuss
common
featur
underli
fusion
viru
cell
membran
present
compound
owe
abil
target
differ
step
process
potenti
broadspectrum
antivir
also
highlight
emerg
antivir
wellestablish
moa
potenti
clinic
develop
fusion
viru
cell
membran
molecular
choreographi
requir
cognat
interact
viral
envelop
protein
host
cell
compon
interfac
viru
cell
membran
review
describ
core
stage
membran
fusion
process
pinpoint
key
common
target
broadspectrum
antivir
target
membran
fusion
viru
entri
virus
dock
onto
cell
membran
engag
viral
receptor
locat
cell
surfac
achiev
close
proxim
envelop
virus
cell
membran
trivial
lipid
bilay
natur
repuls
mainli
owe
electrostat
hydrat
repuls
forc
thu
virus
coopt
wide
array
auxiliari
factor
facilit
cellular
adsorpt
includ
solubl
factor
protein
transferrin
famili
lipoprotein
cell
surfaceassoci
factor
lectin
glycosaminoglycan
competit
attach
cofactor
andor
entri
receptor
basi
classic
inhibitor
viru
entri
box
block
cognat
virusreceptor
interact
obviou
antivir
paradigm
entri
inhibitor
strategi
exemplifi
maraviroc
selzentri
pfizer
small
molecul
inhibit
entri
hiv
isol
use
cc
chemokin
receptor
coreceptor
viru
entri
howev
develop
receptorspecif
entri
inhibitor
vast
major
viral
pathogen
limit
identif
actual
receptor
also
econom
incent
furthermor
broad
divers
viral
receptor
rule
block
virusreceptor
interact
broadspectrum
antivir
strategi
addit
specif
host
cell
receptor
increas
number
ancillari
host
cell
molecul
highlight
enabl
viru
entri
exampl
mani
virus
use
glycosaminoglycan
sialic
acid
glycosphingolipid
andor
lectin
dock
onto
concentr
surfac
target
cell
order
facilit
viru
entri
invas
rel
nonspecif
interact
play
crucial
part
viru
entri
releas
appear
broadli
share
distinct
virus
thu
repres
candid
target
broadspectrum
antivir
sialic
acid
analogu
zanamivir
oseltamivir
act
viral
neuraminidas
inhibitor
prevent
sialic
acid
cleavag
virion
releas
technic
viru
entri
inhibitor
nonetheless
reduc
lung
viral
load
mainstay
influenza
treatment
despit
low
barrier
resist
howev
remov
cell
surfac
sialic
acid
lung
epitheli
cell
seem
viabl
broadspectrum
antivir
strategi
parainfluenza
virus
influenza
virus
depend
sialic
acid
entri
exampl
fludas
ansun
biopharma
inhal
recombin
bacteri
sialidas
shown
efficaci
phase
ii
clinic
trial
influenza
viru
use
success
treat
sever
parainfluenza
viru
diseas
immunocompromis
patient
importantli
hosttarget
therapeut
increas
barrier
emerg
drugresist
viral
strain
decoy
lectin
exampl
cyanovirinn
griffithsin
glycomimet
compet
virus
attach
cell
surfac
also
recent
explor
antivir
may
even
prove
broadspectrum
antivir
although
expect
toxic
administ
systemat
probabl
limit
use
topic
microbicid
final
mani
virus
bind
cell
surfac
receptor
access
host
cell
cytosol
somewher
along
endosom
traffick
pathway
thu
inhibitor
endosom
traffick
andor
acidif
exampl
bafilomycin
nh
cl
commonli
use
virolog
laboratori
studi
mechan
entri
phdepend
virus
vitro
reduc
acidif
endocyt
vesicl
counteract
phtrigger
conform
chang
viral
fusion
glycoprotein
requir
membran
fusion
see
text
inhibitor
potenti
broadspectrum
antivir
even
toward
nonenvelop
virus
howev
mani
chemic
fruit
use
vitro
studi
seem
cytotox
translat
effect
treatment
although
evalu
antivir
vivo
tabl
new
compound
distinct
mechan
action
may
hold
promis
instanc
recent
identifi
aryl
semicarabazon
ega
shown
inhibit
traffick
earli
late
endosom
rather
block
endosom
acidif
engag
proper
receptor
receptor
either
result
direct
viral
fusion
plasma
membran
induc
variou
endocyt
pathway
lead
fusion
intracellular
vesicular
compart
suit
viral
life
cycl
intracellular
compart
along
endosom
pathway
often
process
endosom
proteas
andor
low
ph
condit
trigger
conform
chang
viral
fusion
protein
conform
chang
essenti
membran
fusion
contrast
virus
fuse
directli
cell
surfac
often
reli
host
cellular
secret
proteas
secret
produc
cell
environ
process
envelop
protein
proteolyt
process
metast
viral
fusion
protein
common
prerequisit
prime
viral
fusion
protein
undergo
cascad
conform
chang
forc
merg
viru
host
cell
membran
exampl
cathepsin
emerg
proteas
coopt
sever
acut
pathogen
virus
ebov
sarscov
henipavirus
therefor
cathepsin
inhibitor
sought
potenti
broadspectrum
entri
inhibitor
cathepsindepend
virus
tabl
cathepsin
ubiquit
proteas
requir
mani
host
activ
whether
inhibitor
appropri
therapeut
index
found
remain
determin
recent
thought
three
structur
distinct
class
viral
fusion
protein
involv
fusion
viru
host
cell
membran
fig
hallmark
class
fusion
protein
includ
proteolyt
gener
aminotermin
fusion
peptid
anchor
viru
host
cell
membran
target
fusion
trimer
quaternari
structur
trigger
format
complementari
domain
fold
sixhelix
bundl
structur
postfus
conform
trigger
conform
chang
class
fusion
protein
ph
depend
exampl
influenza
viru
ph
independ
exampl
hiv
exampl
avian
alpharetrovirus
see
class
ii
fusion
protein
compos
almost
entir
threedomain
architectur
di
dii
diii
tightli
fold
fusion
loop
dii
domain
similarli
fusion
peptid
class
fusion
protein
anchor
viru
host
cell
membran
target
fusion
class
ii
fusion
protein
found
flavivirus
denv
wnv
ph
depend
complex
receptor
determin
structur
mix
class
iii
fusion
protein
compris
element
class
class
ii
fusion
protein
domain
domain
fusion
loop
respect
ph
depend
protein
found
exampl
vesicular
stomat
viru
vsv
herpesvirus
three
class
fusion
protein
act
function
trimer
drive
membran
fusion
process
fold
stabl
trimer
postfus
conform
fig
howev
recent
structur
protein
bovin
viral
diarrhoea
viru
bvdv
hcv
indic
fusion
protein
adopt
novel
fold
distinct
fold
class
ii
iii
fusion
protein
notabl
bvdv
hcv
two
diverg
genera
within
flavivirida
famili
includ
genu
flaviviru
member
denv
wnv
possess
typic
class
ii
fusion
protein
mechanist
detail
potenti
new
class
fusion
protein
remain
determin
structur
disulfidelink
protein
thought
fusogen
heterodimer
fusion
protein
despit
differ
differ
class
fusion
protein
even
though
intermedi
conform
fusion
protein
observ
directli
viral
fusion
protein
seem
mediat
membran
fusion
similar
seri
conform
chang
intermedi
structur
fig
fusion
protein
metast
prefus
conform
receptor
engag
trigger
low
ph
lead
destabil
result
exposur
concomit
insert
fusion
peptid
class
loop
class
ii
class
iii
target
cell
membran
extend
prehairpin
intermedi
phi
also
lead
de
novo
format
complementari
unstabl
domain
refold
andor
oligomer
form
energet
favour
structur
fig
cascad
conform
chang
power
merg
outer
leaflet
viru
membran
outer
leaflet
host
cell
membran
hemifus
follow
merg
inner
leaflet
two
membran
culmin
format
fusion
pore
fig
interestingli
although
trigger
conform
chang
fusion
protein
either
ph
depend
ph
independ
class
fusion
protein
avian
alpharetrovirus
requir
type
trigger
case
bind
cognat
receptor
neutral
ph
induc
format
phi
howev
phi
unusu
stabl
longliv
second
lowph
trigger
requir
induc
phi
refold
trimer
hairpin
lead
mix
lipid
bilay
format
fusion
pore
regardless
specif
proteinprotein
interact
ph
condit
trigger
conform
dynam
drive
membran
fusion
essenti
biophys
featur
underli
process
essenti
featur
includ
dramat
transit
viral
membran
posit
curvatur
bilay
spontan
curvatur
j
b
neg
curvatur
j
b
appropri
membran
fluiditi
maintain
complet
process
lipid
bilay
mix
fusion
process
trigger
energet
requir
power
transit
overcom
electrostat
repuls
neg
charg
lipid
head
group
viral
cellular
lipid
bilay
first
second
featur
depend
lipid
sterol
composit
viru
host
cell
membran
wherea
third
featur
provid
variou
nonexclus
sourc
temperatur
ph
enthalpi
associ
conform
chang
protein
essenti
featur
membran
fusion
process
provid
framework
understand
broadspectrum
antivir
discuss
review
seem
target
common
element
either
directli
indirectli
tabl
inde
modul
physicochem
properti
rais
energet
membran
bend
viruscel
fusion
energet
disfavour
would
one
gener
principl
broadspectrum
antivir
strategi
target
viru
fusion
phospholipid
compon
biolog
membran
cyclindr
compound
polar
head
hydrophob
tail
selfassembl
planar
bilay
energi
cost
associ
bend
piec
flat
membran
spheric
vesicl
calcul
use
thermodynam
principl
known
physicochem
properti
lipid
bilay
thu
energi
cost
per
membran
area
creat
sphere
estim
g
bend
bend
rigid
membran
r
vesicl
radiu
bend
rigid
express
k
b
k
b
boltzmann
constant
relat
energi
individu
particl
level
temperatur
ga
constant
r
divid
avogadro
constant
n
absolut
temperatur
sterol
compon
cholesterol
result
pack
specif
phospholipid
speci
within
cholesterolrich
microdomain
decreas
intrins
membran
fluiditi
result
free
diffus
phospholipid
speci
lipid
bilay
convers
phospholipid
unsatur
acyl
chain
pack
homogen
phospholipid
satur
acyl
chain
result
dynam
diffus
phospholipid
bilay
thu
cholesterol
unsatur
phospholipid
increas
decreas
membran
rigid
respect
membran
rigid
rang
k
b
highli
fluid
model
membran
compris
unsatur
phospholipid
k
b
membran
contain
cholesterol
resembl
plasma
membran
composit
mammalian
cell
erythrocyt
sever
factor
influenc
energet
cost
bend
membran
exampl
given
membran
rigid
exponenti
increas
amount
absolut
energi
requir
k
b
nm
bend
membran
vesicl
diamet
get
smaller
see
figur
furthermor
biophysicalmodel
data
illustr
even
minor
increas
membran
rigid
caus
lipophil
photosensit
coupl
larg
decreas
vesicl
radiu
occur
format
fusion
stalk
result
exponenti
insurmount
amount
extra
energi
requir
bend
viral
membran
product
fusion
occur
see
figur
thu
energet
membran
bend
provid
ration
foundat
broadspectrum
antivir
strategi
exploit
sever
consider
energi
barrier
must
overcom
product
virushost
cell
membran
fusion
occur
one
strategi
design
broadspectrum
antivir
target
protein
involv
viral
fusion
process
includ
viral
fusion
protein
greater
understand
differ
step
involv
cascad
conform
chang
result
membran
fusion
biochem
character
domain
expos
phi
variou
fusion
protein
led
ration
design
peptid
inhibitor
antagon
transit
fold
extend
phi
highli
stabl
postfus
conform
fig
first
proof
concept
came
studi
peptid
amino
acid
deriv
carboxytermin
heptad
repeat
domain
class
fusion
protein
peptid
call
also
known
enfuvirtid
fuzeon
roch
clinic
use
salvag
therapi
patient
infect
multidrugresist
hiv
design
target
complementari
domain
tran
fit
interstic
trimer
core
phi
prevent
refold
cognat
domain
ci
thu
antagon
transit
phi
stabl
trimerofhairpin
structur
propos
act
dominantneg
inhibitor
inhibit
entri
much
greater
potenc
lower
halfmaxim
inhibitori
concentr
ic
would
expect
affin
trimer
core
howev
resist
mutat
often
occur
outsid
complementari
region
viral
isol
treat
patient
even
report
becom
depend
entri
indic
still
fulli
understand
moa
nevertheless
paradigm
establish
encourag
develop
analog
fusion
inhibitor
class
viral
fusion
protein
also
led
investig
diiideriv
peptid
inhibitor
class
ii
fusion
protein
basi
function
homolog
domain
class
fusion
protein
diii
domain
class
ii
fusion
protein
although
peptidebas
approach
may
broadli
applic
across
class
viral
fusion
protein
gener
actual
peptid
therapeut
like
specif
viru
close
relat
variant
develop
howev
peptid
deriv
domain
fusion
protein
unexpectedli
display
activ
unrel
virus
exampl
recent
describ
peptid
deriv
membraneproxim
stem
region
rvfv
gc
class
ii
fusion
protein
inhibit
entri
rvfv
also
ebov
vsv
encod
class
class
iii
fusion
protein
respect
structur
model
indic
peptid
compat
expos
complementari
hydrophob
domain
class
fusion
protein
propos
moa
remain
rigor
test
alloster
control
protein
function
thioldisulfid
exchang
emerg
theme
broad
scientif
interest
especi
metast
protein
involv
cell
entri
exampl
thiol
isomeras
prototyp
cell
surfac
protein
disulfid
isomeras
encod
implic
rearrang
intramolecular
disulfid
bond
occur
viral
envelop
protein
fusion
process
review
ref
fig
larg
famili
pdi
protein
usual
resid
endoplasm
reticulum
er
studi
cell
surfac
pdi
regard
viral
entri
unless
otherwis
specifi
typic
refer
howev
lack
specif
inhibitor
pdi
famili
member
except
monoclon
antibodi
coupl
lack
mechan
account
cell
surfac
retent
pdi
stymi
investig
pdi
potenti
therapeut
target
furthermor
assumpt
pdi
druggabl
target
owe
ubiquit
function
er
chaperon
inhibit
would
lead
unaccept
toxic
also
hamper
search
specif
pdi
inhibitor
discoveri
recent
year
may
offer
new
opportun
investig
pdi
druggabl
target
potenti
broadspectrum
antivir
exampl
discoveri
galectin
bind
retain
increas
activ
perhap
also
known
also
known
surfac
cell
provid
mechanist
basi
longstand
observ
pdi
activ
surfac
lymphocyt
macrophag
galectin
effect
function
oligom
form
glycoprotein
lattic
cell
surfac
cluster
cognat
ligand
furthermor
galectin
enhanc
hiv
entri
host
cell
inhibit
monoclon
antibodi
suggest
cell
surfac
inde
modul
viru
entri
sever
studi
identifi
compound
form
specif
thiol
coval
adduct
cystein
residu
activ
site
therefor
serv
specif
inhibitor
propyno
acid
carbamoyl
methylamid
identifi
screen
novel
antitumour
agent
wherea
activ
identifi
screen
cytoprotect
compound
cellular
model
huntington
diseas
pdi
secret
platelet
endotheli
cell
thrombogen
addit
screen
analys
potent
inhibitor
extracellular
pdi
candid
antithrombot
therapi
identifi
also
known
rutin
highli
specif
inhibitor
select
inhibit
relat
pdi
famili
member
also
known
thioredoxin
effect
relev
anim
model
untoward
toxic
concentr
use
thu
pdi
inhibitor
success
develop
treat
diseas
could
leverag
potenti
broadspectrum
antivir
fig
revers
tradit
paradigm
reli
test
activ
differ
compound
specif
viru
highli
specif
pdi
inhibitor
could
use
screen
set
suscept
viral
pathogen
pharmacokinet
safeti
toxic
data
alreadi
obtain
lead
compound
could
appli
relev
anim
model
infect
clearli
side
effect
drug
balanc
potenti
efficaci
antivir
nevertheless
repurpos
fdaapprov
drug
treat
rare
lethal
emerg
infecti
diseas
strategi
endors
fda
medic
countermeasur
initi
mcmi
fdawid
effort
set
facilit
avail
drug
countermeasur
need
control
emerg
infecti
diseas
specul
nitazoxanid
ntz
thiazolid
antiparasit
agent
recent
propos
potenti
pdi
inhibitor
demonstr
broad
antivir
activ
vitro
singl
drug
synergi
antivir
howev
still
unclear
whether
antivir
activ
ntz
directli
relat
antipdi
activ
arbidol
arb
also
known
umifenovir
wellknown
indol
deriv
broadspectrum
antivir
activ
popular
treatment
respiratori
infect
russia
china
unfortun
report
moa
also
broad
pleiotrop
least
case
influenza
viru
viral
resist
arb
map
class
fusion
protein
haemagglutinin
ha
arbresist
ha
variant
mediat
membran
fusion
higher
ph
wildtyp
counterpart
convers
arbbound
ha
variant
requir
lower
ph
wildtyp
protein
transit
lowph
form
phi
data
indic
arbresist
easili
destabil
suggest
arb
inhibit
influenza
viru
entri
stabil
ha
prefus
conform
fig
whether
arb
similar
moa
phdepend
virus
remain
seen
ntz
arb
exemplifi
promis
broadspectrum
antivir
candid
immedi
use
patient
combin
good
bioavail
safe
record
use
patient
oral
formul
avail
arb
broadli
distribut
russia
china
yet
approv
fda
ema
use
western
countri
ntz
approv
fda
treatment
infect
giardia
lamblia
alinia
romark
laboratori
lc
current
global
phase
iii
clinic
trial
influenza
virus
ntz
arb
appear
safe
clinic
profil
offlabel
use
treatment
suscept
viral
pathogen
may
thu
warrant
guid
proper
surrog
anim
efficaci
studi
option
avail
addit
tradit
compound
target
protein
mediat
viral
fusion
emerg
paradigm
broadspectrum
antivir
point
lipid
viru
host
cell
membran
potenti
target
block
viral
fusion
entri
virolyt
antivir
peptid
avp
reminisc
broadspectrum
pleiotrop
antimicrobi
peptid
amp
part
innat
immun
defenc
mechan
present
kingdom
life
date
bestcharacter
avp
gener
small
kda
cation
amphiphil
peptid
activ
probabl
reli
interfaci
hydrophob
inde
avp
engag
electrostat
andor
hydrophob
interact
hydrophob
surfac
fusion
protein
transient
expos
fusion
process
avp
also
interact
membran
lipid
abil
avp
interact
fusion
protein
exemplifi
aforement
fusion
inhibitor
peptid
fig
contrast
abil
avp
interact
membran
lipid
exemplifi
peptid
deriv
nonstructur
protein
hcv
wasp
venom
secretagogu
toxin
mastoparan
deriv
peptid
detergentlik
properti
fig
display
potent
virolyt
activ
variou
envelop
virus
includ
member
flavivirida
paramyxovirida
famili
wnv
denv
hcv
human
respiratori
syncyti
viru
rsv
other
influenza
viru
obviou
differ
could
discern
sensit
resist
virus
puzzl
select
lytic
avp
toward
target
remain
subject
ongo
investig
perhap
case
sever
amp
select
avp
resid
distinct
lipid
composit
viral
target
membran
membran
host
cell
viral
lipidom
profil
help
address
verac
hypothesi
databas
experiment
valid
avp
avpdb
indic
avp
increasingli
investig
therapeut
util
lack
cohes
moa
like
imped
clinic
applic
near
futur
membran
fluiditi
essenti
paramet
govern
energet
membran
curvatur
transit
occur
membran
fusion
positivetoneg
membran
curvatur
transit
occur
viruscel
fusion
fig
fruit
interrog
variou
lipid
either
support
antagon
geometr
constraint
fusion
process
exampl
coneshap
lipid
cholesterol
oleic
acid
tend
favour
membran
fusion
promot
neg
curvatur
therefor
facilit
hemifus
contrast
invertedconeshap
lipid
also
call
wedgelik
lipid
lysolipid
includ
lysophosphatidylcholin
lpc
inhibit
fusion
increas
posit
curvatur
viral
membran
fig
thu
rais
energi
barrier
must
overcom
product
fusion
mediat
viral
fusion
protein
sterol
lipid
composit
essenti
membran
curvatur
fluiditi
remov
andor
addit
speci
viral
andor
cellular
membran
evalu
antivir
strategi
interest
exampl
come
socal
polyunsatur
ertarget
liposom
perl
origin
develop
deliv
antivir
drug
cargo
er
serendipit
perl
found
broadspectrum
antivir
activ
hiv
hcv
hepat
b
viru
hbv
even
antivir
drug
cargo
load
perl
mechanist
investig
indic
perl
trigger
reduct
cellular
level
cholesterol
coneshap
lipid
tend
favour
membran
fusion
virus
even
effici
clinic
approv
cholesterollow
drug
lovastatin
mevacor
merck
also
antivir
effect
hcv
hbv
tabl
perltrigg
cellular
cholesterol
deplet
result
decreas
entri
suscept
virus
sensit
reduc
level
cholesterol
cell
surfac
addit
virus
produc
perltreat
cell
reduc
infect
owe
lower
cholesterol
content
lipid
envelop
bud
virion
fig
phenotyp
could
rescu
addit
exogen
cholesterol
result
confirm
import
cholesterol
within
cellular
viral
membran
least
three
test
virus
hiv
hcv
hbv
thu
perltrigg
cellular
cholesterol
reduct
seem
impair
one
step
replic
cycl
suscept
virus
although
capabl
attract
exact
mechan
mechan
perl
antivir
activ
suscept
virus
remain
character
offtarget
effect
perlinduc
signal
cascad
await
better
definit
invertedconeshap
speci
lysolipid
known
impair
fusion
stabil
viral
lipid
membran
state
posit
membran
curvatur
rais
energet
cost
need
viral
fusion
fig
howev
compound
may
also
act
last
step
membran
fusion
stabil
highli
posit
curv
pore
edg
fig
therebi
prevent
expans
notabl
lysolipid
broadli
antivir
also
cytotox
unstabl
vivo
addit
antifusogen
effect
realiz
millimolar
concentr
readili
revers
although
properti
bode
well
use
lysolipid
experiment
tool
hinder
therapeut
potenti
compound
nonetheless
lysolipid
moa
inspir
ration
design
novel
class
broadspectrum
antivir
term
rigid
amphipath
fusion
inhibitor
rafi
rafi
nonlipid
invertedconeshap
molecul
made
conjug
larg
bulki
hydrophil
head
nucleosid
deriv
smaller
rigid
planar
hydrophob
tail
rafi
geometr
reminisc
lysolipid
exhibit
broadspectrum
antivir
activ
sever
envelop
virus
herp
simplex
viru
hsv
influenza
viru
vsv
hcv
nonenvelop
virus
although
structureact
relationship
analys
sar
analys
show
consist
propos
moa
involv
geometr
antagon
neg
membran
curvatur
subset
rafi
appear
activ
furthermor
rafi
seem
act
irrevers
ic
tensofnanomolar
rang
collect
observ
inconsist
pure
geometr
moa
suggest
addit
mechan
respons
antivir
effect
mediat
rafi
therefor
although
greater
potenc
invertedconeshap
rafi
rel
lysolipid
ic
nanomolar
rang
rafi
versu
millimolar
rang
lysolipid
support
potenti
broadspectrum
antivir
addit
studi
need
clarifi
moa
compound
group
amphiphil
thiazolidin
deriv
exemplifi
small
molecul
found
exhibit
broadspectrum
antivir
activ
could
inhibit
virus
differ
famili
envelop
virus
test
includ
variou
virus
filovirida
paramyxovirida
arenavirida
flavivirida
herpesvirida
famili
nonenvelop
virus
compound
lightactiv
membranetarget
singlet
oxygen
gener
also
known
type
ii
photosensit
gener
compound
oxid
cc
doubl
bond
present
unsatur
phospholipid
result
cistotran
isomer
bond
introduc
polar
hydroperoxi
ooh
group
highli
hydrophob
acyl
chain
phospholipid
photochem
induc
chang
alter
critic
biophys
properti
membran
although
exact
chang
occur
follow
lipid
oxid
unknown
first
project
plasma
membran
surfac
area
occupi
oxid
phospholipid
predict
increas
owe
migrat
hydroperoxi
group
polar
plane
surfac
bilay
second
oxid
phospholipid
predict
cluster
microdomain
order
reduc
hydrophob
repuls
forc
newli
incorpor
polar
group
fig
inde
featur
physic
observ
nanoscop
scale
use
atom
forc
microscopi
enabl
quantit
assess
induc
decreas
membran
thick
expans
area
per
unsatur
phospholipid
altogeth
rearrang
membran
nanoarchitectur
result
increas
posit
curvatur
reduc
fluiditi
togeth
increas
energet
requir
membran
fusion
use
panopli
assay
involv
model
membran
live
virus
treat
deriv
lipid
oxid
viral
membran
shown
correl
increas
lipid
pack
reduc
membran
fluiditi
also
link
impair
viral
fusion
furthermor
observ
extend
group
thiazolidin
deriv
followup
class
novel
deriv
exampl
also
chemic
unrel
rafi
compound
inde
close
examin
activ
rafi
reveal
consist
presenc
hydrophob
polycycl
perylen
group
reminisc
wellknown
photosensit
exampl
hypocrellin
hypericin
suggest
rafi
act
photosensit
followup
studi
confirm
antivir
activ
exemplar
rafi
abolish
absenc
light
thu
strictli
depend
light
exposur
furthermor
antivir
activ
could
revers
scaveng
character
type
ii
membranetarget
photosensit
regard
antivir
activ
converg
moa
chemic
distinct
class
broadspectrum
antivir
target
lipid
compon
membran
fusion
underscor
generaliz
propos
moa
despit
encourag
vivo
activ
ref
clinic
potenti
membranetarget
photosensit
broadspectrum
antivir
vivo
seem
current
limit
photophys
hurdl
includ
depth
tissu
penetr
visibl
light
nonetheless
advanc
photochemistri
nanotechnolog
may
help
overcom
hurdl
exampl
recent
develop
includ
upconvert
fluoresc
nanoparticl
abl
convert
tissuepenetr
long
wavelength
rel
shorter
one
within
absorpt
spectra
studi
establish
novel
paradigm
broadspectrum
antivir
identifi
moa
membraneintercal
photosensit
involv
photooxid
unsatur
phospholipid
lead
biophys
chang
neg
affect
abil
viral
membran
undergo
fusion
also
compound
effect
antivir
concentr
induc
notic
biophys
chang
metabol
activ
cell
membran
also
contain
unsatur
phospholipid
target
ref
due
fact
biogen
cellular
membran
benefit
cellular
repar
capac
static
viral
membran
lack
futur
class
broadspectrum
antivir
may
exploit
gener
principl
final
bavituximab
peregrin
pharmaceut
repres
one
clinic
promis
broadspectrum
antivir
paradigm
bavituximab
immunoglobulin
monoclon
antibodi
direct
anion
phospholipid
phosphatidylserin
phosphatidylserin
normal
restrict
inner
leaflet
cellular
plasma
membran
flip
expos
cell
surfac
apoptot
event
viral
replic
often
trigger
cellular
apoptot
state
neovirion
bud
produc
cell
piec
membran
contain
phosphatidylserin
outer
leaflet
phosphatidylserin
inde
detect
variou
viral
envelop
target
uniqu
featur
select
exposur
phosphatidylserin
viral
envelop
membran
healthi
cell
bavituximab
potenti
use
broadspectrum
antivir
fig
inde
bavituximab
prove
efficaci
murin
cytomegaloviru
mcmv
arenaviru
pichind
viru
vsv
bavituximab
current
evalu
variou
haemorrhag
fever
virus
hiv
phase
phase
ii
clinic
trial
treatment
chronic
hcv
infect
coinfect
hiv
hcv
potenti
use
bavituximab
viral
diseas
futur
greatli
enhanc
current
evalu
antineoplast
therapeut
howev
exact
rang
virus
display
suffici
amount
phosphatidylserin
outer
leaflet
membran
success
target
bavituximab
remain
determin
despit
divers
array
viral
fusion
mechan
even
wider
rang
put
broadspectrum
antivir
character
target
virushost
cell
membran
fusion
process
antivir
broad
spectrum
sens
target
virus
within
famili
protein
within
viral
fusion
protein
class
wherea
other
broad
spectrum
sens
target
requir
particular
fusion
trigger
furthermor
antivir
truli
broad
spectrum
target
physicochem
basi
underli
membran
fusion
event
exploit
physiolog
differ
static
viral
membran
metabol
activ
cellular
membran
repar
capac
exampl
avp
sterolbind
agent
membraneintercal
photosensit
may
damag
viru
cell
membran
thu
toxic
extent
howev
key
paradigm
recogn
physiolog
differ
inact
viral
activ
cellular
membran
exploit
develop
broadspectrum
antivir
relev
issu
whether
drug
toxic
known
toxic
certain
cellular
process
arbitrari
concentr
whether
drug
toxic
antivir
concentr
treatment
condit
addit
riskbenefit
calcul
much
toxic
accept
must
depend
acut
pathogen
viral
infect
avail
lack
thereof
effect
therapeut
option
exampl
chronic
infect
hiv
hcv
drug
need
taken
daili
prolong
period
therapeut
select
longterm
safeti
issu
paramount
case
abund
highli
effect
therapi
alreadi
exist
barrier
use
broadspectrum
antivir
high
convers
current
ebola
epidem
west
africa
shortterm
toxic
potenti
antivir
would
weigh
lack
effect
option
valid
reason
support
efficaci
potenti
drug
rapid
expans
broadspectrum
antivir
approach
directli
indirectli
target
lipid
involv
viral
membran
fusion
underscor
need
comprehens
character
viral
lipidom
lipidom
studi
alreadi
reveal
cell
activ
lipid
composit
primari
human
cell
type
differ
thu
like
virus
grown
commonli
use
laboratori
cell
line
accur
reflect
viral
phenotyp
caus
transmiss
infecti
diseas
affect
efficaci
antivir
test
call
standard
protocol
cell
type
use
antivir
evalu
standard
acceler
translat
develop
novel
broadspectrum
antivir
exampl
use
relev
vitro
surrog
system
use
human
pluripot
stem
cellderiv
primari
cell
type
determin
antivir
efficaci
therapeut
index
halfmaxim
cytotox
concentr
cc
ic
could
provid
biolog
relev
inform
even
antivir
test
anim
model
similarli
recent
advanc
threedimension
bioprint
microfluid
organsonchip
allow
gener
relev
tissu
model
drug
discoveri
toxicolog
thu
sar
studi
broadspectrum
antivir
target
viral
fusion
even
hone
relev
tissu
model
eventu
anim
test
altogeth
technolog
facilit
translat
basic
understand
viral
fusion
process
broadspectrum
therapi
target
process
work
broadspectrum
antivir
fusion
support
us
nation
institut
health
nih
grant
project
grant
pacif
infecti
diseas
transmit
reservoir
nonreservoir
host
usual
refer
diseas
caus
pathogen
jump
nonhuman
anim
human
purpos
review
antivir
act
least
two
distinct
virus
two
differ
famili
via
common
mechan
action
virus
surround
lipid
bilay
deriv
host
cell
membran
envelop
protect
virion
content
harbour
among
cellderiv
viral
encod
protein
viral
protein
necessari
attach
fusion
viru
entri
process
merg
two
initi
distinct
lipid
bilay
togeth
singl
lipid
bilay
viral
envelop
protein
mediat
actual
merg
viral
host
cell
membran
membranebound
vesicl
shuttl
plasma
membran
lysosom
play
major
part
endomembran
system
eukaryot
cell
host
factor
allow
specif
attach
viru
target
cell
initi
entryfus
cascad
pertain
viral
fusion
protein
transient
intermedi
andor
energet
unfavour
prefus
state
variou
trigger
conform
chang
enabl
metast
prefus
protein
fold
least
energet
stabl
postfus
state
cathepsin
phdepend
proteas
part
found
endolysosom
compart
eukaryot
cell
ratio
toxic
effect
antivir
concentr
compound
extend
metast
intermedi
conform
viral
fusion
protein
fold
back
stabl
postfus
conform
state
membran
fusion
lipid
constitu
outer
leaflet
two
juxtapos
bilay
mix
point
virushost
cell
membran
fusion
inner
leaflet
two
bilay
still
distinct
virion
content
access
host
cell
cytoplasm
enthalpi
h
system
thermodynam
function
equival
intern
energi
system
u
plu
product
volum
v
pressur
p
exert
surround
thu
hupv
small
volum
viral
fusion
protein
h
u
structur
motif
compris
sevenresidu
repeat
follow
hpphcpc
pattern
h
p
c
repres
hydrophob
polar
charg
amino
acid
respect
secretagogu
substanc
trigger
secret
anoth
substanc
lipid
smaller
hydrophil
head
group
rel
hydrophob
acyl
chain
particip
neg
membran
curvatur
thu
facilit
hemifus
lipid
larger
hydrophil
head
group
rel
hydrophob
acyl
chain
particip
posit
membran
curvatur
thu
impair
viral
vesicular
fusion
lipid
molecul
result
natur
hydrolysi
phospholipid
one
acyl
chain
tail
region
instead
two
present
phospholipid
give
lysolipid
invertedcon
shape
analys
optim
pharmacophor
druglik
properti
hit
compound
molecul
absorb
radiant
energi
light
photon
transfer
molecul
total
lipid
composit
specif
virus
viral
fusion
protein
mediat
membran
fusion
via
diverg
structur
shown
preand
postfus
structur
repres
class
fusion
protein
haemagglutinin
ha
influenza
viru
class
ii
fusion
protein
e
protein
dengu
viru
class
iii
fusion
protein
g
protein
vesicular
stomat
viru
fusion
intermedi
crystal
pure
schemat
model
consist
bodi
experiment
evid
present
free
virion
harbour
one
three
class
metast
fusion
protein
prefus
conform
state
fusion
peptid
class
loop
class
ii
iii
buri
insid
protein
variou
trigger
receptor
bind
proteas
trim
low
ph
induc
conform
rearrang
result
anchor
fusion
peptid
loop
red
triangl
amino
terminu
fusion
protein
juxtapos
cellular
membran
anchor
lead
concurr
format
complementari
amphipath
domain
purpl
cyan
cylind
class
protein
class
ii
protein
prehairpin
extend
intermedi
simplic
one
monom
repres
prehairpin
intermedi
alway
trimer
newli
expos
domain
unstabl
refold
form
energet
favour
structur
enthalpi
associ
conform
chang
forc
mix
outer
leaflet
viral
membran
outer
layer
cellular
membran
result
format
hemifus
stalk
inner
leaflet
lipid
bilay
come
contact
begin
mix
open
pore
viral
cellular
membran
trimer
structur
refold
highli
stabl
postfus
conform
like
fusion
peptid
loop
transmembran
domain
orang
cylind
interact
degre
promot
transit
hemifus
stalk
pore
format
subsequ
pore
enlarg
allow
deliveri
viral
content
target
cell
cytosol
lipid
composit
essenti
membran
curvatur
fluiditi
remov
addit
lipid
speci
evalu
antivir
strategi
exampl
cation
amphiphil
antivir
peptid
avp
detergentlik
properti
high
concentr
result
format
pore
lead
micel
viral
membran
polyunsatur
endoplasm
reticulumtarget
liposom
perl
shown
potenti
broadspectrum
antivir
deplet
cellular
viral
membran
cholesterol
cholesterol
deplet
reduc
fluiditi
membran
impair
negativecurvatur
transit
necessari
fusion
viral
cellular
membran
wedgelik
invertedconeshap
molecul
amphiphil
avp
increas
spontan
posit
curvatur
viral
membran
lipid
bilay
rais
barrier
energi
requir
power
membran
fusion
mediat
viral
fusion
protein
similarli
membranetarget
type
ii
photosensit
gener
singlet
oxygen
within
plane
viral
membran
singlet
oxygen
oxid
unsatur
phospholipid
induc
chang
nanoarchitectur
viral
membran
conduc
membran
fusion
cluster
oxid
phospholipid
result
differenti
lipid
pack
reduc
fluiditi
increas
posit
curvatur
increas
area
per
lipid
molecul
reduc
membran
thick
phospholipidspecif
antibodi
target
particular
phospholipid
speci
enrich
viral
membran
phosphatidylserin
thu
block
viral
attach
entri
exampl
potenti
broadspectrum
antivir
target
event
entri
cascad
envelop
virus
clinic
use
evalu
vivo
human
nonhuman
primat
evalu
vivo
nonprim
evalu
vivo
diseas
exampl
cancer
mucos
protect
aerosol
dominantneg
also
shown
bind
phosphatidylserin
block
phagocytosi
via
phosphatidylserin
receptor
cell
cytochalasin
b
inhibit
actin
polymer
block
actin
monom
addit
chlorpromazin
chloroquin
long
known
lower
endosom
ph
effect
pleiotrop
molecular
target
respect
inhibit
endocytosi
remain
unknown
ega
newli
discov
compound
inhibit
host
factor
involv
earli
late
endosom
traffick
identifi
host
factor
remain
identifi
arbidol
pleiotrop
effect
also
affect
sever
step
differ
viral
life
cycl
